Core Viewpoint - Quest Diagnostics Incorporated (DGX) is positioned for growth with expected earnings increases and a strong performance relative to market indices [1][5]. Financial Performance - DGX is set to release its Q1 2026 earnings on April 21, with analysts projecting an EPS of $2.35, reflecting a 6.3% increase from $2.21 in the same quarter last year [2]. - For fiscal 2026, the projected EPS is $10.60, up 7.6% from $9.85 in fiscal 2025, with further growth expected to $11.44 in fiscal 2027, representing a year-over-year increase of approximately 7.9% [3]. - The company has consistently exceeded Wall Street's EPS estimates in the last four quarters, with reported EPS figures showing positive surprises [4]. Stock Performance - DGX stock has increased by 18.9% over the past 52 weeks, outperforming the S&P 500 Index's rise of 13.4% [5]. - Following the release of better-than-expected Q4 2025 earnings, DGX stock rose by 7.4%, with revenue surpassing estimates and management raising full-year forecasts [6]. Analyst Sentiment - Analysts maintain a "Moderate Buy" rating on DGX, with nine recommending a "Strong Buy" and nine advising "Hold" [7]. - The average analyst price target for DGX is $218.53, indicating a potential upside of 10.3% from current levels [7].

Core Viewpoint - Quest Diagnostics Incorporated (DGX) has shown strong performance in the diagnostic testing sector, with significant stock price appreciation and positive earnings results, indicating robust investor confidence and growth potential. Group 1: Company Overview - Quest Diagnostics is based in Secaucus, New Jersey, and has a market capitalization of $23 billion, providing diagnostic testing and services both domestically and internationally [1]. Group 2: Stock Performance - DGX shares have outperformed the broader market, surging 21.8% over the past 52 weeks and 18.4% year-to-date, compared to the S&P 500 Index's return of 11.9% over the same period [2]. - The stock has also outperformed the State Street Healthcare Select Sector SPDR ETF (XLV), which rose by 8.7% over the past 52 weeks [3]. Group 3: Earnings Performance - On February 10, Quest Diagnostics reported better-than-expected Q4 2025 earnings, with revenue of $2.81 billion, exceeding forecasts, and adjusted EPS of $2.18, also surpassing Wall Street projections [6]. - Management raised its full-year revenue forecast to between $10.8 billion and $10.9 billion, with adjusted EPS expected to be in the range of $9.63 to $9.83 [6]. Group 4: Analyst Expectations - For the year ending December 2026, analysts project a 7.7% year-over-year growth in EPS to $10.61 on a diluted basis, with a strong earnings surprise history [7]. - Among 18 analysts covering DGX, the consensus rating is "Moderate Buy," with nine "Strong Buy" ratings and nine "Holds" [7]. Group 5: Price Target and Analyst Ratings - The stock's configuration has become more bullish, with nine "Strong Buy" ratings, up from eight a month ago [8]. - Mizuho analyst Ann Hynes maintained an "Outperform" rating and raised the price target from $210 to $235, indicating a potential upside of 14.4% based on the Street-high target [8].

Core Insights - Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing and services, valued at $20.6 billion, with a national network of laboratories and patient service centers [1] Performance Overview - DGX shares have outperformed the broader market, gaining 15.4% over the past year compared to the S&P 500 Index's 12.3% increase [2] - Year-to-date, DGX stock is up 23.3%, surpassing the S&P 500's 12.9% rise [2] Comparison with Industry Peers - DGX's performance is also superior to the SPDR S&P Health Care Services ETF (XHS), which has gained about 9.8% over the past year [3] - On a year-to-date basis, DGX's returns outshine the ETF's 12.8% gains [3] Financial Results - In Q3, DGX reported an adjusted EPS of $2.60, exceeding Wall Street's expectation of $2.51, with revenue of $2.8 billion, beating the forecast of $2.7 billion [4] - For the full year, DGX expects adjusted EPS in the range of $9.76 to $9.84 and revenue between $10.96 billion and $11 billion [4] Analyst Expectations - Analysts project DGX's EPS to grow 9.6% to $9.79 for the current fiscal year [5] - DGX has consistently beaten consensus estimates in the last four quarters, with a current consensus rating of "Moderate Buy" from 18 analysts [5] Analyst Ratings and Price Targets - The current analyst configuration is less bullish than three months ago, with nine analysts suggesting a "Strong Buy" [6] - Piper Sandler Companies maintained a "Neutral" rating on DGX, raising the price target to $200, indicating a potential upside of 7.6% [6] - The mean price target of $198.71 suggests a 6.9% premium, while the highest price target of $215 indicates a potential upside of 15.6% [6]